Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Biochemistry

• Publication date

  2010-11-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1021/bi101208kPMID 21028906PMCID PMC2991413
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tetrabenazine

  2011cited by this paper
• Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2

  2011cited by this paper
• HD Therapeutics - CHDI Fifth Annual Conference.

  2010cited by this paper
• Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases.

  2010cited by this paper
• Structural Diversity of Triplet Repeat RNAs*♦

  2010influential reference
• Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.

  2010cited by this paper
• Therapeutic gene silencing strategies for polyglutamine disorders.

  2010cited by this paper
• Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.

  2010cited by this paper
• Trinucleotide repeats in human genome and exome

  2010cited by this paper
• Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

  2010cited by this paper
• Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal models.

  2010cited by this paper
• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.

  2009cited by this paper
• Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals.

  2009cited by this paper
• Allele‐specific silencing of mutant Huntington’s disease gene

  2009cited by this paper
• Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs

  2009influential reference
• Tetrabenazine

  2009cited by this paper
• Reversal of RNA Dominance by Displacement of Protein Sequestered on Triplet Repeat RNA

  2009cited by this paper
• Allele‐Selective Inhibition of Mutant Huntingtin by Peptide Nucleic Acid‐Peptide Conjugates, Locked Nucleic Acid, and Small Interfering RNA

  2009cited by this paper
• A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference.

  2009cited by this paper
• The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies

  2009cited by this paper
• Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl]pyrrolocytosine.

  2009cited by this paper
• Sustained effects of nonallele‐specific Huntingtin silencing

  2009cited by this paper
• Identification and Allele-Specific Silencing of the Mutant Huntingtin Allele in Huntington's Disease Patient-Derived Fibroblasts

  2008cited by this paper
• Thermodynamics of DNA-RNA heteroduplex formation: effects of locked nucleic acid nucleotides incorporated into the DNA strand.

  2008cited by this paper
• The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.

  2008cited by this paper
• Chemically modified siRNA: tools and applications.

  2008cited by this paper
• The Medicinal Chemistry of Oligonucleotides

  2008cited by this paper
• Huntington's disease.

  2007cited by this paper
• Trinucleotide repeat disorders.

  2007cited by this paper
• Chemical modification: the key to clinical application of RNA interference?

  2007cited by this paper
• LNA-modified oligonucleotides effectively drive intramolecular-stable hairpin to intermolecular-duplex state.

  2007cited by this paper
• Five- and six-membered conformationally locked 2',4'-carbocyclic ribo-thymidines: synthesis, structure, and biochemical studies.

  2007cited by this paper
• Allele-specific RNA interference for neurological disease

  2006cited by this paper
• Thermodynamic, counterion, and hydration effects for the incorporation of locked nucleic acid nucleotides into DNA duplexes.

  2006cited by this paper
• Antisense oligonucleotide therapy for neurodegenerative disease.

  2006cited by this paper
• Design of LNA probes that improve mismatch discrimination

  2006cited by this paper
• Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine

  2005cited by this paper
• Axonal transport failure in neurodegenerative disorders: the case of Huntington's disease.

  2005cited by this paper
• Thermodynamic stability of RNA structures formed by CNG trinucleotide repeats. Implication for prediction of RNA structure.

  2005cited by this paper
• siRNA-mediated inhibition of endogenous Huntington disease gene expression induces an aberrant configuration of the ER network in vitro.

  2005influential reference
• p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease.

  2005cited by this paper
• Progress in antisense technology.

  2004cited by this paper
• Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic?

  2004cited by this paper
• Early changes in Huntington’s disease patient brains involve alterations in cytoskeletal and synaptic elements

  2004cited by this paper
• A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease.

  2004cited by this paper
• Molecular architecture of CAG repeats in human disease related transcripts.

  2004cited by this paper
• Protein aggregation and neurodegenerative disease

  2004cited by this paper
• Analysis of Thermal Melting Curves

  2003cited by this paper
• Molecular Biology of Huntington's Disease (HD) and HD-Like Disorders

  2003cited by this paper
• Allele-specific silencing of dominant disease genes

  2003cited by this paper
• Triplex formation with 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) having C3'-endo conformation at physiological pH.

  2003cited by this paper
• Efficient RNase H-directed cleavage of RNA promoted by antisense DNA or 2'F-ANA constructs containing acyclic nucleotide inserts.

  2003cited by this paper
• 2'-O,4'-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug.

  2002cited by this paper
• Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design.

  2002cited by this paper
• Thermal stability of PNA/DNA and DNA/DNA duplexes by differential scanning calorimetry.

  1999cited by this paper
• Correlation of Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide Designed to Inhibit ICAM-1

  1999cited by this paper
• Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation.

  1999cited by this paper
• Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA

  1999cited by this paper
• D-ALTRITOL NUCLEIC ACIDS (ANA) : HYBRIDISATION PROPERTIES, STABILITY, AND INITIAL STRUCTURAL ANALYSIS

  1999cited by this paper
• Analysis of the cooperative thermal unfolding of the td intron of bacteriophage T4.

  1999cited by this paper
• The effect of two antipodal fluorine-induced sugar puckers on the conformation and stability of the Dickerson-Drew dodecamer duplex [d(CGCGAATTCGCG)]2.

  1998cited by this paper
• Stability and Structural Features of the Duplexes Containing Nucleoside Analogues with a Fixed N‐Type Conformation, 2′‐O,4′‐C‐Methyleneribonucleosides.

  1998influential reference
• LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition

  1998cited by this paper
• HYBRIDS OF RNA AND ARABINONUCLEIC ACIDS (ANA AND 2'F-ANA) ARE SUBSTRATES OF RIBONUCLEASE H

  1998cited by this paper
• Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2'-O,4'- C-methyleneribonucleosides

  1998cited by this paper
• Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion

  1997cited by this paper
• Reduced penetrance of the Huntington's disease mutation.

  1997cited by this paper
• Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats.

  1996cited by this paper
• An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers.

  1995cited by this paper
• Inactivation of the mouse Huntington's disease gene homolog Hdh.

  1995cited by this paper
• Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes.

  1995cited by this paper
• A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats.

  1994cited by this paper
• Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease

  1993cited by this paper
• Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets.

  1993cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

  1993cited by this paper
• Treatment of Huntington's disease with clonazepam.

  1988cited by this paper
• Treatment of Huntington's disease with clonazepam.

  1988cited by this paper
• Huntington's disease

  1984cited by this paper

• CRISPR-based gene therapy for huntington’s disease: current advances and future prospects

  2025cites this paper
• Oligonucleotide-Based Therapeutics for Neurodegenerative Disorders: Focus on Antisense Oligonucleotides.

  2025cites this paper
• Sequencing-guided design of genetically encoded small RNAs targeting CAG repeats for selective inhibition of mutant huntingtin

  2024cites this paper
• An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment.

  2024cites this paper
• Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing

  2024cites this paper
• Full-Length Transcript Phasing with Third-Generation Sequencing.

  2023cites this paper
• SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington’s disease

  2022cites this paper
• An RNA-targeting CRISPR–Cas13d system alleviates disease-related phenotypes in Huntington’s disease models

  2022cites this paper
• The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.

  2022cites this paper
• Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology

  2022cites this paper
• BTT_A_270657 141..160

  2022cites this paper
• Emerging Therapies for Huntington’s Disease – Focus on N-Terminal Huntingtin and Huntingtin Exon 1

  2022cites this paper
• Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases

  2022cites this paper
• Efficient Cloning and Sequence Validation of Repetitive and High GC-Content Short Hairpin RNAs

  2022cites this paper
• Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease

  2022cites this paper
• RNA-Targeting CRISPR/Cas13d System Eliminates Disease-Related Phenotypes in Pre-clinical Models of Huntington’s Disease

  2022cites this paper
• Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS

  2021cites this paper
• CAG repeat instability in embryonic stem cells and derivative spermatogenic cells of transgenic Huntington’s disease monkey

  2021cites this paper
• Knocking Down Barriers: Advances in siRNA Delivery

  2021cites this paper
• Molecular Strategies to Target Protein Aggregation in Huntington’s Disease

  2021cites this paper
• Reliable Resolution of Full-Length Huntingtin Alleles by Quantitative Immunoblotting

  2021cites this paper
• Antisense oligonucleotide drugs for neurological and neuromuscular disease

  2020cites this paper
• Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities

  2020cites this paper
• Therapeutic Update on Huntington’s Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies

  2020cites this paper
• Stereocontrolled Oligonucleotides for Nucleic Acid Therapeutics: A Perspective

  2020cites this paper
• Acid Gapmers and Conjugates Potently Silence ADAM 33 , an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA

  2019cites this paper
• Disease-Modification in Huntington’s Disease: Moving Away from a Single-Target Approach

  2019cites this paper
• RNA suppression in animal models of HD, and the problems with its clinical translation

  2019cites this paper
• Molecular Dynamics simulations applied to structural and dynamical transitions of the HTT protein: A review.

  2019cites this paper
• Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease

  2019cites this paper
• Chromatin accessibility and transcription dynamics during in vitro astrocyte differentiation of Huntington’s Disease Monkey pluripotent stem cells

  2019cites this paper
• The effects of huntingtin-lowering: what do we know so far?

  2019cites this paper
• Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide

  2019cites this paper
• Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.

  2019cites this paper
• Antisense therapies for movement disorders

  2019cites this paper
• Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease

  2019cites this paper
• Recent advances in molecular therapies for neurological disease: triplet repeat disorders.

  2019cites this paper
• Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease

  2019cites this paper
• Combination of stem cell and gene therapy ameliorates symptoms in Huntington’s disease mice

  2019cites this paper
• Antisense oligonucleotides: the next frontier for treatment of neurological disorders

  2018cites this paper
• Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7

  2018cites this paper
• Oligonucleotide therapeutics in neurodegenerative diseases

  2018cites this paper
• Therapeutic approaches to Huntington disease: from the bench to the clinic

  2018cites this paper
• Huntingtin protein: A new option for fixing the Huntington's disease countdown clock

  2018cites this paper
• Antisense Oligonucleotides for Treatment of Neurological Diseases

  2018cites this paper
• Influence of mismatched and bulged nucleotides on SNP-preferential RNase H cleavage of RNA-antisense gapmer heteroduplexes

  2017cites this paper
• The chemical evolution of oligonucleotide therapies of clinical utility

  2017cites this paper
• Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

  2017cites this paper
• Két autofágia aktiváló kismolekula, az AUTEN-67 és az AUTEN-99 hatásának vizsgálata Drosophila melanogaster Huntington-kór modellben

  2017cites this paper
• Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA

  2017cites this paper
• RNA-directed off/on switch of RNase H activity using boronic ester formation.

  2017cites this paper
• Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models

  2017cites this paper
• Huntington’s Disease—Update on Treatments

  2017cites this paper
• Pharmacodynamic Biomarkers for HTT-Lowering Therapies : A White Paper

  2017cites this paper
• Evaluation de différentes stratégies thérapeutiques antisens pour le traitement de la maladie de Huntington

  2017influential citation
• Nanoparticulate strategies for the treatment of polyglutamine diseases by halting the protein aggregation process†

  2017cites this paper
• CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression

  2017cites this paper
• Gene suppression approaches to neurodegeneration

  2017cites this paper
• Carbocyclic C‐C Bond Formation: Intramolecular Radical Ring Closure to Yield Diastereomerically Pure (7′S‐Me‐ or 7′R‐Me‐) Carba‐LNA Nucleotide Analogs

  2017cites this paper
• Fluorinated Nucleotide Modifications Modulate Allele Selectivity of SNP-Targeting Antisense Oligonucleotides

  2017cites this paper
• The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain

  2017cites this paper
• Modified Antisense Oligonucleotides and Their Analogs in Therapy of Neuromuscular Diseases

  2016cites this paper
• The Medicinal Chemistry of Therapeutic Oligonucleotides.

  2016cites this paper
• Antisense Oligonucleotide Tool in Therapy for Polyglutamine Neurodegenerative Disorders

  2016cites this paper
• Manifestation of Huntington’s disease pathology in human induced pluripotent stem cell-derived neurons

  2016cites this paper
• Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.

  2016cites this paper
• Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington’s disease

  2016cites this paper
• Allele-specific regulation of mutant Huntingtin by Wig1, a downstream target of p53.

  2016cites this paper
• Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease

  2016cites this paper
• New Strategies for Drug Discoveries of Neurodegenerative Disease: Degradation of Pathogenic Mutant Proteins

  2016cites this paper
• Analysis and Modulation of PACT, DICER and MBNL1 in the Context of Myotonic Dystrophy Type I

  2016cites this paper
• Use of human stem cells in Huntington disease modeling and translational research.

  2016cites this paper
• Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.

  2016cites this paper
• Characterization of HTT Inclusion Size, Location, and Timing in the zQ175 Mouse Model of Huntington´s Disease: An In Vivo High-Content Imaging Study

  2015cites this paper
• G‐quadruplexes: Emerging roles in neurodegenerative diseases and the non‐coding transcriptome

  2015cites this paper
• Oligonucleotide Therapies: The Past and the Present

  2015cites this paper
• Progress on Gene Therapy, Cell Therapy, and Pharmacological Strategies Toward the Treatment of Oculopharyngeal Muscular Dystrophy

  2015cites this paper
• A Tandem Oligonucleotide Approach for SNP-Selective RNA Degradation Using Modified Antisense Oligonucleotides

  2015cites this paper
• Pharmacodynamic Biomarkers for HTT-Lowering Therapies

  2015cites this paper
• The role of natural antisense transcripts in the pathogenesis of nervous system diseases

  2015cites this paper
• Delivering a disease-modifying treatment for Huntington's disease.

  2015cites this paper
• Movement disorders 3 Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

  2014cites this paper
• RNA Structural Analysis Based on Thermal Denaturation

  2014cites this paper
• Effect of 2′-O-methyl/thiophosphonoacetate-modified antisense oligonucleotides on huntingtin expression in patient-derived cells

  2014cites this paper
• Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.

  2014cites this paper
• Structure of the myotonic dystrophy type 2 RNA and designed small molecules that reduce toxicity.

  2014cites this paper
• Differential effects on allele selective silencing of mutant huntingtin by two stereoisomers of α,β-constrained nucleic acid.

  2014cites this paper
• Preventing Formation of Toxic N-Terminal Huntingtin Fragments Through Antisense Oligonucleotide-Mediated Protein Modification

  2014cites this paper
• Oligonucleotide-based strategies to combat polyglutamine diseases

  2014cites this paper
• Drugging unconventional targets: insights from Huntington's disease.

  2014cites this paper
• Targeting the r(CGG) Repeats That Cause FXTAS with Modularly Assembled Small Molecules and Oligonucleotides

  2014cites this paper
• Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients

  2014cites this paper
• Exploring the Effect of Sequence Length and Composition on Allele-Selective Inhibition of Human Huntingtin Expression by Single-Stranded Silencing RNAs

  2014cites this paper
• Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.

  2014cites this paper
• Huntington’s disease investigated using sheep as a model

  2014cites this paper
• Personalized gene silencing therapeutics for Huntington disease

  2014cites this paper
• In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides.

  2014cites this paper
• Oligonucléotides de modulation d'arn ayant des caractéristiques perfectionnées pour le traitement de troubles neuromusculaires

  2013cites this paper
• Mapping the Landscape of Acquired Vulnerabilities in Ovarian Cancer

  2013cites this paper
• Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions.

  2013cites this paper